We use cookies to ensure that we give you the best experience on our website.
When you use our platform without an account you need to read and accept the
Terms of Service, Data Policy and Disclaimer(s).
Market Cap.:2.7 B
M
Market Capitalization - Sizes
Here you can see how we classify a market capitalization.
XS
< 100 Mil.
S
> 100 Mil.
M
> 1 Bil.
L
> 10 Bil.
XL
> 100 Bil.
P/E:-12.47
x50.41Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
Concrete for "Biotechnology" in United States
EPS: -2.1086,
P/E: 50.4118
EPS:-3.24
x
0.65
Industry Within Country Benchmark (IWCB)
The multiplier shows you the relation between a reported metric, e.g. Earnings Per Share (EPS)
and the μ EPS value of the corporate's industry.
We exclude other countries from the average calculation in order to
take into account the specific economic and regulatory conditions in that country.
Concrete for Biotechnology in United States
EPS: -2.1086,
P/E: 50.4118
Earnings Call
No. The last one was
10 months, 1 week ago
Dividend Waiting Time
We compute the average time difference between dividend payments
and assign an indicator that holds a general grade for that frequency.
Low
Average time between dividend payments is less than 3 months.
Neutral
Average time between dividend payments is between 3 to 6 months.
High
Average time between dividend payments is more than 6 months.
n.A.
Latest Dividends History
Each bar represents a dividend payment made within the last 12 months, with the bar's height relative to the maximum dividend paid within that timeframe.
See all Dividends.
Yield
Payout
Volume LevelVolume Deviation Rating System (VDRS)
We compare the 15-minute delayed volume to the average volume and grade the percentual deviation.
High
Deviation >= 20%
Moderate High
Deviation between 10% to 20%
Moderate
Deviation between -10% to 10%
Moderate Low
Deviation between -20% to -10%
Low
Deviation between <= -20%
μ 2,044,466
3,281,100
Moderate Low
Performance Ranks (Intraday)A system to benchmark KDNY's relative intraday performance.
Each star represents "20% have worse results", e.g. 4/5 stars symbolize that the corporate had a better result than 80% of the benchmark compotion.
United States:
1502nd
out of
2160
Healthcare:
446th
out of
792
Biotechnology:
137th
out of
227
Peer Group:
4th
out of
5
About
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the …
About
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the …
Berkshire Hathaway
Profile, Qualitative, Financials ...
Overview
Royal Bank Of Canada
Valuation Models & History
Financials
Alphabet Inc. - Competitors
SNAP, TWLO, PINS, META ...
Comp.
Amazon.com, Inc.
Risks/AI
NLP Analyzed Risk Factors, AI Arguments
Apple Inc. vs. Peers & Industry Benchmarks
Benchmarks Industry
Peter Lynch Screener
Strategy